Bristol-Myers Squibb Company (BMY) |
|
60.13 -0.63 (-1.04%)
|
10-24 22:55 |
|
Open: |
60.83 |
Pre. Close: |
60.76 |
|
High:
|
61.22 |
Low:
|
60.0717 |
|
Volume:
|
6,435,152 |
Market Cap:
|
135,529M |
|
|
|
|
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in New York City, New York and currently employs 23,300 full-time employees. The firm's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The firm's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. The company offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
61.393 - 61.733 |
61.733 - 62.01 |
|
Low:
|
59.011 - 59.496 |
59.496 - 59.89 |
|
Close:
|
59.42 - 60.136 |
60.136 - 60.717 |
|
Technical analysis |
as of: 2020-10-23 4:41:20 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 72.91 One year: 85.15 |
| Support: |
Support1: 59.01 Support2: 56.90 |
| Resistance: |
Resistance1: 62.42 Resistance2: 72.91 |
| Pivot: |
60.58  |
| Moving Average: |
MA(5): 60.47 MA(20): 60.36
MA(100): 59.84 MA(250): 60.24 |
| MACD: |
MACD(12,26): 0.16 Signal(9): 0.19 |
| Stochastic oscillator: |
%K(14,3): 56.06 %D(3): 58.44 |
| RSI: |
RSI(14): 48.73 |
| 52-week: |
High: 68.34 Low: 45.76 Change(%): 8.2 |
| Average Vol(K): |
3-Month: 998611 10-Days: 903262 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.BMY has closed above bottom band by 38.9%. Bollinger Bands are 13.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sat, 24 Oct 2020
Hot Stock on Radar: Bristol-Myers Squibb Company (BMY) - Armenian Reporter
Fri, 23 Oct 2020
Gear up for the change! Bristol-Myers Squibb Company (BMY) has hit the volume of 1924602 - The InvestChronicle
Thu, 22 Oct 2020
Bristol Myers Squibb Stock Looks Attractive At $60 - Forbes
Wed, 21 Oct 2020
Bristol-Myers Squibb: Stock Price Trapped In A $50-$65 Range - Don't Expect That To Change Soon - Seeking Alpha
Mon, 19 Oct 2020
Were Hedge Funds Right About Bristol Myers Squibb Company (BMY)? - Yahoo Finance
Sat, 17 Oct 2020
Why I Think Bristol Myers Squibb Is Too Cheap to Miss - The Motley Fool
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers General |
| Shares Out. (M) |
2,250 |
| Shares Float (M) |
2,250 |
|
% Held by Insiders
|
0.11 |
|
% Held by Institutions
|
79.09 |
|
Shares Short (K)
|
14,360 |
|
Shares Short P. Month (K)
|
14,450 |
Stock Financials |
|
EPS
|
-0.280 |
|
EPS Est This Year
|
3.000 |
|
EPS Est Next Year
|
3.230 |
|
Book Value (p.s.)
|
21.780 |
|
Profit Margin
|
-1.61 |
|
Operating Margin
|
21.69 |
|
Return on Assets (ttm)
|
5.2 |
|
Return on Equity (ttm)
|
-1.6 |
|
Qtrly Rev. Growth
|
61.5 |
|
Gross Profit (p.s.)
|
8.413 |
|
Sales Per Share
|
15.493 |
|
EBITDA (p.s.)
|
6.222 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
12,760 |
|
Levered Free Cash Flow (M)
|
15,790 |
Stock Valuations |
|
PE Ratio
|
-214.75 |
|
PEG Ratio
|
0.81 |
|
Price to Book value
|
2.76 |
|
Price to Sales
|
3.88 |
|
Price to Cash Flow
|
10.60 |
Stock Dividends |
|
Dividend
|
1.760 |
|
Forward Dividend
|
1.800 |
|
Dividend Yield
|
0.03 |
|
Dividend Pay Date
|
2020-11-01 |
|
Ex-Dividend Date
|
2020-09-30 |
|
7 Binary Options
|
|
Your Ad Here
|
|
